243 related articles for article (PubMed ID: 20810784)
41. Activity and cellular functions of the deubiquitinating enzyme and polyglutamine disease protein ataxin-3 are regulated by ubiquitination at lysine 117.
Todi SV; Scaglione KM; Blount JR; Basrur V; Conlon KP; Pastore A; Elenitoba-Johnson K; Paulson HL
J Biol Chem; 2010 Dec; 285(50):39303-13. PubMed ID: 20943656
[TBL] [Abstract][Full Text] [Related]
42. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice.
Colomer Gould VF; Goti D; Pearce D; Gonzalez GA; Gao H; Bermudez de Leon M; Jenkins NA; Copeland NG; Ross CA; Brown DR
Neurobiol Dis; 2007 Sep; 27(3):362-9. PubMed ID: 17632007
[TBL] [Abstract][Full Text] [Related]
43. Identification of a novel site of interaction between ataxin-3 and the amyloid aggregation inhibitor polyglutamine binding peptide 1.
Knight PD; Karamanos TK; Radford SE; Ashcroft AE
Eur J Mass Spectrom (Chichester); 2018 Feb; 24(1):129-140. PubMed ID: 29334808
[TBL] [Abstract][Full Text] [Related]
44. NEDD8: a new ataxin-3 interactor.
Ferro A; Carvalho AL; Teixeira-Castro A; Almeida C; Tomé RJ; Cortes L; Rodrigues AJ; Logarinho E; Sequeiros J; Macedo-Ribeiro S; Maciel P
Biochim Biophys Acta; 2007 Nov; 1773(11):1619-27. PubMed ID: 17935801
[TBL] [Abstract][Full Text] [Related]
45. Ataxin-3 is a multivalent ligand for the parkin Ubl domain.
Bai JJ; Safadi SS; Mercier P; Barber KR; Shaw GS
Biochemistry; 2013 Oct; 52(42):7369-76. PubMed ID: 24063750
[TBL] [Abstract][Full Text] [Related]
46. The Machado-Joseph disease-associated expanded form of ataxin-3: Overexpression, purification, and preliminary biophysical and structural characterization.
Contessotto MGG; Rosselli-Murai LK; Garcia MCC; Oliveira CLP; Torriani IL; Lopes-Cendes I; Murai MJ
Protein Expr Purif; 2018 Dec; 152():40-45. PubMed ID: 30036587
[TBL] [Abstract][Full Text] [Related]
47. Investigation of the Josephin Domain protein-protein interaction by molecular dynamics.
Deriu MA; Grasso G; Licandro G; Danani A; Gallo D; Tuszynski JA; Morbiducci U
PLoS One; 2014; 9(9):e108677. PubMed ID: 25268243
[TBL] [Abstract][Full Text] [Related]
48. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.
Chai Y; Koppenhafer SL; Shoesmith SJ; Perez MK; Paulson HL
Hum Mol Genet; 1999 Apr; 8(4):673-82. PubMed ID: 10072437
[TBL] [Abstract][Full Text] [Related]
49. p62/sequestosome 1 regulates aggresome formation of pathogenic ataxin-3 with expanded polyglutamine.
Zhou L; Wang H; Chen D; Gao F; Ying Z; Wang G
Int J Mol Sci; 2014 Aug; 15(9):14997-5010. PubMed ID: 25158237
[TBL] [Abstract][Full Text] [Related]
50. Molecular analyses of Machado-Joseph disease.
Kobayashi T; Kakizuka A
Cytogenet Genome Res; 2003; 100(1-4):261-75. PubMed ID: 14526188
[No Abstract] [Full Text] [Related]
51. The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits Lys63 linkages in mixed linkage ubiquitin chains.
Winborn BJ; Travis SM; Todi SV; Scaglione KM; Xu P; Williams AJ; Cohen RE; Peng J; Paulson HL
J Biol Chem; 2008 Sep; 283(39):26436-43. PubMed ID: 18599482
[TBL] [Abstract][Full Text] [Related]
52. Structure validation of the Josephin domain of ataxin-3: conclusive evidence for an open conformation.
Nicastro G; Habeck M; Masino L; Svergun DI; Pastore A
J Biomol NMR; 2006 Dec; 36(4):267-77. PubMed ID: 17096206
[TBL] [Abstract][Full Text] [Related]
53. FAT10 protein binds to polyglutamine proteins and modulates their solubility.
Nagashima Y; Kowa H; Tsuji S; Iwata A
J Biol Chem; 2011 Aug; 286(34):29594-600. PubMed ID: 21757738
[TBL] [Abstract][Full Text] [Related]
54. Enhanced molecular mobility of ordinarily structured regions drives polyglutamine disease.
Lupton CJ; Steer DL; Wintrode PL; Bottomley SP; Hughes VA; Ellisdon AM
J Biol Chem; 2015 Oct; 290(40):24190-200. PubMed ID: 26260925
[TBL] [Abstract][Full Text] [Related]
55. Toward understanding Machado-Joseph disease.
Costa Mdo C; Paulson HL
Prog Neurobiol; 2012 May; 97(2):239-57. PubMed ID: 22133674
[TBL] [Abstract][Full Text] [Related]
56. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence.
Bichelmeier U; Schmidt T; Hübener J; Boy J; Rüttiger L; Häbig K; Poths S; Bonin M; Knipper M; Schmidt WJ; Wilbertz J; Wolburg H; Laccone F; Riess O
J Neurosci; 2007 Jul; 27(28):7418-28. PubMed ID: 17626202
[TBL] [Abstract][Full Text] [Related]
57. Valosin-containing protein (VCP/p97) is an activator of wild-type ataxin-3.
Laço MN; Cortes L; Travis SM; Paulson HL; Rego AC
PLoS One; 2012; 7(9):e43563. PubMed ID: 22970133
[TBL] [Abstract][Full Text] [Related]
58. Protein Environment: A Crucial Triggering Factor in Josephin Domain Aggregation: The Role of 2,2,2-Trifluoroethanol.
Visentin C; Navarro S; Grasso G; Regonesi ME; Deriu MA; Tortora P; Ventura S
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30042316
[TBL] [Abstract][Full Text] [Related]
59. Capturing the Conformational Ensemble of the Mixed Folded Polyglutamine Protein Ataxin-3.
Sicorello A; Różycki B; Konarev PV; Svergun DI; Pastore A
Structure; 2021 Jan; 29(1):70-81.e5. PubMed ID: 33065068
[TBL] [Abstract][Full Text] [Related]
60. Ataxin-3 binds VCP/p97 and regulates retrotranslocation of ERAD substrates.
Zhong X; Pittman RN
Hum Mol Genet; 2006 Aug; 15(16):2409-20. PubMed ID: 16822850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
